We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Lactotripeptides (Val-Pro-Pro / Ile-Pro-Pro)
Two milk-casein-derived tripeptides — Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) — produced by fermenting milk with Lactobacillus helveticus or hydrolysing casein. They inhibit ACE in vitro and have been studied extensively for blood pressure. Honest appraisal: multiple meta-analyses find a small, statistically-significant drop in systolic/diastolic BP, but the effect is modest, heterogeneous, larger in Japanese than Western trials, and dented by clear publication bias plus outright-null trials (e.g. the Dutch Engberink RCT).
What the evidence says
Most Lactotripeptides studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 2005–2015 with a typical study size of 135 participants.
Based on 12 studies · 7 meta-analyses · 3 RCTs · 334 total participants
Confidence
HighBy outcome
Lactotripeptides has an evidence score of 4.5/10 — emerging evidence based on 12 indexed studies, including 7 meta-analyses. Two milk-casein-derived tripeptides — Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP) — produced by fermenting milk with Lactobacillus helveticus or hydrolysing casein. They inhibit ACE in vitro and have been studied extensively for blood pressure. Honest appraisal: multiple meta-analyses find a small, statistically-significant drop in systolic/diastolic BP, but the effect is modest, heterogeneous, larger in Japanese than Western trials, and dented by clear publication bias plus outright-null trials (e.g. the Dutch Engberink RCT). Representative study: PMID 25608938.
The commonly studied dose of Lactotripeptides is ~3-5 mg combined VPP + IPP per day (the dose used in most positive fermented-milk trials). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Casein Hydrolysate
Mostly mechanism / observationalA milk-derived bioactive peptide — a tryptic hydrolysate of bovine αs1-casein standardized to the decapeptide α-casozepine (Lactium) — marketed for stress, anxiety, and sleep. Honest appraisal: the mechanism is real and food-derived (α-casozepine binds the benzodiazepine site of the GABA-A receptor in vitro), and a handful of small human RCTs show modest reductions in stress symptoms and cortisol plus some sleep-diary improvements. But several trials are industry-linked, two well-designed sleep RCTs were null on their primary endpoint, and effects are small. Well-tolerated; this is an ordinary dietary supplement, not a drug.
Explore: Best supplements for Vitality & Longevity
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Seven meta-analyses find a small, statistically-significant blood-pressure drop, but the effect is modest, heterogeneous, larger in Japanese than Western trials, dented by publication bias, and contradicted by null RCTs like the Dutch Engberink trial.
Lactotripeptides are the casein-derived tripeptides isoleucine-proline-proline (IPP) and valine-proline-proline (VPP), generated when milk is fermented with Lactobacillus helveticus or casein is hydrolysed with Aspergillus oryzae protease.
Both peptides inhibit angiotensin-converting enzyme (ACE) in vitro, the same target as ACE-inhibitor blood-pressure drugs, and they survive gastrointestinal digestion well enough to reach the circulation intact (in vitro and pig pharmacokinetic data confirm absorption, albeit at a low fractional dose).
This is a food-derived, well-tolerated dietary peptide found in fermented-milk products — not a research compound.
The honest evidence picture is 'small but real, with real caveats.' At least seven meta-analyses of randomized placebo-controlled trials report statistically-significant reductions in systolic blood pressure (pooled effects roughly -1.3 to -5 mmHg) and smaller diastolic reductions.
But the effect is consistently larger in Japanese/Asian studies than in European ones (e.g.
Cicero 2011: SBP -6.9 mmHg in Asians vs a non-significant -1.2 mmHg in Caucasians), benefit concentrates in (pre)hypertensive rather than normotensive people, and several analyses (Fekete 2015, Pripp 2008) explicitly flag publication bias and 'small-study effects' that shift the true effect toward less impressive numbers.
A well-conducted Dutch RCT (Engberink 2008) found no effect on office, home, or 24-h ambulatory BP and no in-vivo ACE inhibition.
Net: lactotripeptides may offer a modest, drug-adjunct, lifestyle-modification-style BP benefit — most plausibly in mildly hypertensive individuals — but they are far weaker than antihypertensive medication and should not be presented as a replacement for it.
VPP and IPP competitively inhibit angiotensin-converting enzyme (ACE1) in vitro — the same renin-angiotensin-system target as ACE-inhibitor drugs — reducing formation of the vasoconstrictor angiotensin II. The in-vivo relevance is debated: some trials saw no measurable plasma ACE inhibition.
Their proline-rich structure resists gastrointestinal peptidases, so a fraction of the intact tripeptides survives digestion and is absorbed (shown in Caco-2 monolayers and a pig pharmacokinetic model), allowing them to reach the circulation in active form.
Beyond ACE inhibition, some trials report improved central arterial compliance and arterial stiffness, consistent with an endothelial/vascular-tone effect — though this mechanism is less firmly established than the ACE-inhibition rationale.
How Lactotripeptides works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
~3-5 mg combined VPP + IPP per day (the dose used in most positive fermented-milk trials)
Take with food
| Form | Type |
|---|---|
| 💊Fermented milk (Lactobacillus helveticus) | Recommended |
| 💊Casein hydrolysate | Alternative |
| 💊Tablet/concentrate | Alternative |
Fermented-milk products are the best-studied delivery; benefit appears tied to delivering ~3-5 mg VPP+IPP/day rather than to the specific food matrix.
Compare Lactotripeptides vs Casein Hydrolysate →Minimum: 4 weeks
Optimal: 8 weeks
Cycling: Not required
Note: Most commonly taken once daily as a fermented-milk drink; no validated optimal time of day.
Dose-response data unavailable. The current published research for Lactotripeptides does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Meta-analyses pool a statistically-significant but modest systolic drop (~2-5 mmHg); individual trials range from clearly positive to fully null.
Diastolic reductions are consistently smaller than systolic (often ~1-2 mmHg) and inconsistent across populations.
Benefit is larger in Japanese/Asian trials and in (pre)hypertensive people; European trials and normotensive subjects often show little or no effect.
Well-conducted Western RCTs (e.g. the Dutch Engberink trial) found no BP effect at all, and publication bias likely inflates the pooled estimate.
Avoid — these are casein-derived peptides.
Lactotripeptides occur naturally in fermented-milk foods and are likely safe as a dietary component; dedicated supplement-dose trials in pregnancy are lacking, so use normal dietary judgment and consult a clinician before using concentrated products.
Safe to combine in most cases, but monitor BP for additive lowering and do not substitute for prescribed therapy.
Theoretical additive blood-pressure-lowering effect via the same RAAS target; trials suggest concomitant antihypertensive medication does not blunt the (small) peptide effect, but monitor for additive hypotension if combining.
Tip: Discontinue if dairy-related GI symptoms occur
Tip: Choose a low-lactose preparation or a non-fermented hydrolysate/tablet form
Timing is flexible for Lactotripeptides — consistent daily use matters more than the time of day. Delivered in fermented-milk drinks, sour-milk products, or tablets; usually taken once daily with no strict time-of-day requirement.
Lactotripeptides is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are generally well tolerated; side effects comparable to placebo in trials, dairy-related GI upset (in lactose-intolerant individuals consuming milk-based products). Use caution if any of these apply to you: Milk / dairy allergy (these are milk-casein-derived peptides); Galactosemia (avoid milk-based products).
Bonito Peptides
Mostly mechanism / observationalShort ACE-inhibitory peptides from enzyme-digested dried bonito (Katsuobushi) fish muscle — notably the dipeptide Val-Tyr ("VY") and the prodrug-type pentapeptide LKPNM — sold as a food-derived supplement for blood pressure. Honest appraisal: a handful of small, mostly Japanese, often industry-linked RCTs show a modest blood-pressure drop in people with mild/high-normal hypertension, on the same ACE-inhibition mechanism as related fish/sardine and milk (lactotripeptide) peptides. The effect is small, the trials are small, and benefit concentrates in (pre)hypertensive people — not normotensives.